Lexicon announces new post-hoc analysis of data on INPEFA

Lexicon Pharmaceuticals announced a new post-hoc analysis of clinical data showing that INPEFA, a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related events across a diverse population of patients, including patients with preserved ejection fraction, HFpEF. Researchers noted that INPEFA appeared to be particularly effective in reducing the risk of heart failure events in patients with an obesity-related HFpEF phenotype. These findings, based on a pooled, patient-level analysis of data from the SOLOST-WHF and SCORED pivotal clinical trials, were presented today at the Annual Congress of the Heart Failure Association of the European Society of Cardiology, ESC, in Lisbon, Portugal. This new analysis assessed the impact of obesity, along with sex and age, on the effects of INPEFA on the primary composite endpoint of cardiovascular death and heart failure events in patients with left ventricular ejection fraction greater than or equal to 50%. Previously, SOLOIST-WHF and SCORED data demonstrated that INPEFA, a dual oral inhibitor of SGLT2 and SGLT1, is effective in reducing the risk of CV death and HF-related outcomes across the LVEF range. Data from a total of 1,932 patients were included in the analysis. In this population, 18.1% of patients experienced a primary endpoint event. Males and females demonstrated comparable event rates, 18.3% and 18.0% respectively; however, older age and higher BMI were associated with an increased number of patients at risk for primary endpoint events. Within the subgroup characterized by higher BMI, INPEFA therapy resulted in a favorable response for patients with BMI greater than or equal to 30 kg/m. Researchers also noted that both sex and age subgroups had a consistent response to INPEFA